[ad_1]
Photo source, fake images
A preliminary analysis result showed that the coronavirus vaccine developed jointly by Pfizer and Bioentech is effective in preventing more than 90% of new coronavirus infection (Corona 19).
Pfizer and Bioentech said it was a “critical day for science and humanity.”
The vaccine has been tested in 43,500 people in six countries and safety concerns have yet to be raised.
The developer plans to apply for emergency approval for the vaccine later this month.
This is the first time a vaccine has been developed in such a short period of time and it has been shown to be very effective.
Big obstacles remain, but the scientific community greatly applauded the news, with some saying that everything could return to normal next spring.
“I’m probably the first person to say that everything will be back to normal next spring,” said John Bell, a professor of medicine at the University of Oxford.
Corona 19: Can you believe that the vaccine made in China has started to vaccinate?
How effective is this vaccine?
Vaccines (and improved treatments) are believed to be the best way out of the constraints that sustain our lives under the COVID-19 crisis.
Based on data from clinical trials, vaccinations are required twice every three weeks. According to clinical trials conducted in the United States, Germany, Brazil, Argentina, South Africa and Turkey, 90% of them are protected from COVID-19 one week after the second vaccination.
However, the data published this time is not the results of the final analysis, but is based on the analysis of 94 clinical trial volunteers infected with Corona 19. The more precise efficacy of this vaccine may change once the results are available. of the final analysis.
Pfizer Chairman Albert Bulla said: “We are a significant step closer to a breakthrough that will help end the global health crisis.”
Bioentech founder Ugur Sahin said this was a “watershed moment”.
When will this vaccine be available?
Some can get vaccinated during the year.
Pfizer and Bioentique say that safety data can be prepared before the third week of November to request regulatory approval for the vaccine.
Without approval for use, vaccination cannot be started.
It is said that the developer will be able to deliver 50 million doses (one dose) by the end of this year and about 1.3 billion doses by the end of 2021. This vaccine requires two doses per person.
The UK will receive 10 million doses by the end of this year and an additional 30 million doses have already been placed.
Who will get the vaccine first?
Since there aren’t enough supplies available for everyone to get the vaccine right away, countries around the world are struggling with who to get the vaccine first.
Medical workers will be the first to be vaccinated and the elderly will be prioritized.
The UK will give priority to the elderly in nursing homes and nursing home workers.
He has not made a final decision yet, however, and it could change depending on how the vaccine works for different age groups and the spread of COVID-19, the UK government said.
Those under the age of 50 without other health problems will be the last to receive the vaccine.
Is there a possibility of other problems with the vaccine?
The data released this time are only provisional, so there are many doubts that have not been resolved.
It is not yet known if people who receive the vaccine will stop transmitting Corona 19 or if they will only develop symptoms. Furthermore, it is not yet known whether it is equally effective for high-risk groups such as the elderly.
The bigger question is how long your immunity lasts. This can take months and even years.
Many challenges remain, from large-scale manufacture of vaccines to shipping them for vaccination to large numbers of people. This is because the vaccine must be stored at a cryogenic temperature of -80 degrees Celsius.
The vaccine appears to be safe in large-scale clinical trials, but nothing is 100% safe, even a common antipyretic drug.
How does this vaccine work?
There are about 10 vaccines that are in phase 3, the final stage of the clinical trial, but this is the first vaccine that has produced results.
This vaccine was developed completely experimentally called ‘RNA vaccine’. It is a method of training the immune system by injecting part of the virus genome into the human body.
Previous clinical trials revealed that the vaccine produces both antibodies and T cells, which are two types of immune systems, to fight the coronavirus.
The mechanism of action of the RNA vaccine.
